Abstract
Background
Controversy still exists regarding the position of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis of colorectal carcinoma. The goal of the current study was to evaluate the opinions about this treatment among Dutch oncologic surgeons and medical oncologists.
Methods
An online survey was sent to all known Dutch oncologic surgeons (n = 459) and medical oncologists (n = 363) representing the respective departments of 84 hospitals. A comparison was made between surgeons and oncologists.
Results
185 eligible responses were received from 71 hospitals, resulting in a response rate of 23 % for individuals and a response rate of 85 % for hospitals. Overall, 65 % of respondents regarded CRS+HIPEC as effective with sufficient evidence, 29 % responded that CRS+HIPEC is probably effective without sufficient evidence, and 7 % of respondents regards HIPEC as probably ineffective. Medical oncologists were less convinced of the effectiveness of CRS+HIPEC than surgeons (P = 0.006). Of all the respondents, 68 % indicated that they regard CRS+HIPEC as a standard treatment for patients with peritoneal dissemination of colorectal carcinoma (77 % of surgeons vs 54 % of oncologists, P = 0.001). Additionally, 68 % of respondents regard CRS+HIPEC as potentially curative (77 % of surgeons vs 54 % of oncologists, P = 0.001).
Conclusions
Approximately 30 % of physicians who treat colorectal carcinoma do not regard CRS+HIPEC as standard care. Surgeons appear to be significantly more in favor of this treatment than medical oncologists. This study shows that efforts should be made to improve knowledge and increase acceptance of CRS and HIPEC in colorectal cancer treatment among medical oncologists and surgeons.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Sugarbaker PH (1995) Peritonectomy procedures. Ann Surg 221(1):29–42
Cao C, Yan TD, Black D et al (2009) A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 16(8):2152–2165
Hompes D, D’Hoore A, Wolthuis A et al (2014) The use of oxaliplatin or mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study. J Surg Oncol 109(6):527–532
Verwaal VJ, van Ruth S, de Bree E et al (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21(20):3737–3743
Spiegle G, Schmocker S, Huang H et al (2013) Physicians’ awareness of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer carcinomatosis. Can J Surg 56(4):237–242
Thomassen I, Bernards N, van Gestel YR et al (2014) Chemotherapy as palliative treatment for peritoneal carcinomatosis of gastric origin. Acta Oncol 53(3):429–432
Klaver YL, Lemmens VE, Creemers GJ et al (2011) Population-based survival of patients with peritoneal carcinomatosis from colorectal origin in the era of increasing use of palliative chemotherapy. Ann Oncol 22(10):2250–2256
Berwick DM (2003) Disseminating innovations in health care. JAMA 289(15):1969–1975
Van Cutsem E, Nordlinger B, Cervantes A et al (2010) Advanced colorectal cancer: ESMO clinical practice guidelines for treatment. Ann Oncol 21(Suppl 5):v93–v97
(2011) Diagnosis and management of colorectal cancer. Scottish Intercollegiate Guidelines Network (SIGN), Edinburgh
Poston GJ, Tait D, O’Connell S et al (2011) Diagnosis and management of colorectal cancer: summary of NICE guidance. BMJ 9(343):d6751
Benson AB, Venook AP, Bekaii-Saab T et al (2014) Colon cancer, version 3. J Natl Compr Canc Netw. 12(7):1028–1059
Australian Cancer Network Colorectal Cancer Guidelines Revision Committee (2005) Guidelines for the prevention, early detection and management of colorectal cancer. The Cancer Council Australia and Australian Cancer Network, Sydney
Pox C, Aretz S, Bischoff SC et al (2013) S3-guideline colorectal cancer version 1.0. Z Gastroenterol 51(8):753–854
(2014) National working group on gastrointestinal cancers. Colorectal carcinoma, national guideline. version 3.0
Grossmann I, de Bock GH, van de Velde CJ et al (2007) Results of a national survey among Dutch surgeons treating patients with colorectal carcinoma. Current opinion about follow-up, treatment of metastasis, and reasons to revise follow-up practice. Colorectal Dis 9(9):787–792
Wevers KP, Hoekstra-Weebers JE, Speijers MJ et al (2014) Cutaneous melanoma: medical specialists’ opinions on follow-up and sentinel lymph node biopsy. Eur J Surg Oncol 40(10):1276–1283
Conflict of interest
The authors report no conflicts of interest in this work.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Braam, H.J., Boerma, D., Wiezer, M.J. et al. Cytoreductive surgery and HIPEC in treatment of colorectal peritoneal carcinomatosis: experiment or standard care? A survey among oncologic surgeons and medical oncologists. Int J Clin Oncol 20, 928–934 (2015). https://doi.org/10.1007/s10147-015-0816-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-015-0816-5